Astec Lifesciences Ltd reported a 30.3% increase in consolidated total income to Rs. 91.6 crore for Q1 FY26, with a reduced EBITDA loss of Rs. 10.5 crore compared to a loss of Rs. 45.3 crore in the same quarter last year. This performance reflects growth in their enterprise and CDMO businesses on July 28, 2025.